WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Osteoporosis Efficacy Criteria v15, The proportion of patients with new fracture has outcome assessment Non-vertebral fracture, FDA Efficacy Criteria for Osteoporosis additional variables for efficacy consideration Concomitant Medications that affect bone, Bone Mineral Density (BMD) measured at Time points defined by protocol, Quantitative Morphometry assesses Decrease in vertebral height, Bone Mineral Density (BMD) measured in secondarily 1/3 distal radius, Blood for - Bone specific alkaline phosphatase(BSAP) - Serum Osteocalcin (OC) - P1NP - P1CP - Serum NTX, - Pyridinolines - CTX - NTX - Deoxypyridinoline (DPD) to determine bone resorption, Observation or Assessment is used to monitor the effectiveness of Therapeutic Intervention, Radiographic Report include Etiology of fracture, Etiology of fracture instnatiated by - No trauma - Low trauma, Decrease in vertebral height assessed as Relative % change from baseline, Therapeutic Efficacy Endpoint is the intersection of Observation or Assessment, Patient's Medical History includes Patient's Medical History Details, Absolute change derived from Vertebral height measurement, Non-vertebral fracture is confirmed by Radiographic Test, Semi-Quantitative Assessment measured for vertebrae T4 - L5, Urine for - Pyridinolines - CTX - NTX - Deoxypyridinoline (DPD), Area measured in cm^2, The proportion of patients with new fracture has outcome assessment Vertebral fracture (morphometric / clinical), Decrease in vertebral height assessed as Absolute change